When is the latest time for Erdafitinib to be launched in China?

Erdafitinib (Erdafitinib) is a targeted drug mainly used to treat patients with locally advanced or metastatic urothelial carcinoma (mUC; bladder cancer ), especially those with susceptibilityFGFR3 gene alterations. After years of research and development and clinical trials, the therapeutic effect of erdafitinib has gradually been recognized globally. For the Chinese market, the latest approval time of erdafitinib is January 8, 2025, which marks the official launch of the drug in China. Once marketed, erdafitinib will provide a new targeted therapy option in the treatment of patients with urothelial cancer, especially those who have failed to respond to traditional treatments or whose disease has progressed.

Erdafitinib is approved in multiple markets around the world under the trade name Balversa (Balversa). The approval of the drug was endorsed by the National Medical Products Administration and provides more advanced treatment options for patients with urothelial cancer in China. As a targeted drug, erdafitinib has extensive clinical support for its application worldwide, and its launch is expected to fill the gap in the Chinese market in the field of specific cancer treatment. Although the drug has been approved in many countries and regions around the world, its entry into the Chinese market means that patients with urothelial cancer will have access to more treatment opportunities, especially for those who have failed to achieve adequate efficacy in traditional treatment options.

For patients,the launch date of January 8, 2025 will be a critical node, meaning they can get help from this therapy through health insurance or purchasing drugs. However, although the drug is already available in China, some patients may need to wait for the official supply of the drug, especially in the early stages, as the introduction of new drugs often faces supply issues. As the demand for this drug in the domestic market gradually increases, the accessibility of erdafitinib is expected to gradually increase.

Reference materials：https://www.balversa.com/